Aurobindo Pharma USA Gets FTC Approval for USD 250 Million Lannett Acquisitions
New Jersey, June 22 (TNT) Aurobindo Pharma USA, Inc., a wholly owned subsidiary of Aurobindo Pharma, has received approval from the U.S. Federal Trade Commission (FTC) for its proposed acquisition of Lannett Company, paving the way for the transaction to be completed before the end of June 2026.
The deal, valued at USD 250 million on a cash-free, debt-free basis, including normalized working capital, is expected to strengthen Aurobindo’s position in the U.S. generic pharmaceutical market, the pharma company said in a release on Monday..
Lannett, based in Pennsylvania, develops and markets a diversified portfolio of complex generic medicines, including non-opioid controlled substances.
The acquisition will significantly expand Aurobindo USA’s offerings in this segment while adding a key U.S.-based manufacturing facility to its network.
The Seymour, Indiana manufacturing facility acquired through the transaction has the capacity to scale production to around four billion doses annually, enhancing Aurobindo USA’s domestic manufacturing footprint and supporting efforts to strengthen pharmaceutical supply chain resilience in the United States.
Aurobindo said the acquisition is expected to be immediately accretive to the Group’s earnings per share and generate operational efficiencies, SG&A synergies and integration benefits.
It will also enhance the company’s portfolio through a differentiated pipeline of complex generics and controlled-substance products.
Commenting on the development, Aurobindo Pharma USA Chief Executive Officer Swami S. Iyer said the acquisition represents a compelling strategic and financial opportunity that will accelerate revenue growth, strengthen U.S.-based manufacturing capabilities and expand the company’s presence in complex non-opioid controlled substances.
Lannett Chief Executive Officer Tim Crew said joining forces with Aurobindo would help make the company’s medicines more affordable and accessible by leveraging Aurobindo’s scale, resources and market reach.
The transaction is expected to create long-term value through portfolio expansion, operational synergies and increased manufacturing capacity, the company said.
TNT TS
